Sandercock Colin 4

What Happened
Colin Sandercock, SVP and General Counsel of Cue Biopharma, received a derivative equity award on April 9, 2026: a stock option for 200,000 shares reported at an exercise price of $0.00 (no immediate cash paid). The reported transaction value is $0 on the Form 4 because this was a grant of a derivative instrument, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-09; Form 4 filed 2026-04-10 (timely filing).
• Transaction type/code: A — Grant/Award (derivative).
• Amount: 200,000 share-equivalent stock option units; reported price $0.00; reported value $0.
• Vesting/other footnote: The option vests over four years — 25% on the one-year anniversary, remainder in equal semi-annual installments thereafter.
• Shares owned after transaction: Not disclosed in the provided filing.
• No indication of immediate sale or cashless exercise in this filing.

Context
This is a standard executive equity grant intended to align long-term incentives; options typically have value only if the company’s share price rises above the exercise price when and if exercised. Because this was a grant (not a purchase or sale), it should be interpreted as compensation, not a direct bullish or bearish trade by the insider.